EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones

Jenna Yager iD, Kristina M Brooks, Jennifer Brothers, Kathleen Mulligan, Raphael Landovitz, Daniel Reirden, Carrie Glenny, Meena Malhotra, Peter L Anderson, Sybil Hosek

AIDS Research and Human Retroviruses · 2022-11 · 38 (11) · 840-846

DOI: 10.1089/aid.2022.0043 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift AIDS Research and Human Retroviruses, online erschienen am 03.11.2022. Verfasst von Jenna Yager und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Transgender Persons, Anti-HIV Agents, HIV Infections, Pre-Exposure Prophylaxis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The transgender community has expressed concerns regarding drug-drug interactions between HIV-pre-exposure prophylaxis (PrEP) and gender-affirming hormones. In this study, we evaluated emtricitabine (F, FTC)/tenofovir (TFV) disoporoxil fumarate (TDF) pharmacokinetics (PK) among adolescent and young adult transgender persons receiving gender-affirming hormone therapy (GAHT). This was a prospective, observational study among transgender women (TW) and men (TM) without HIV, 15–24 years of age, receiving GAHT (estradiol with/without spironolactone, or testosterone). Participants received 1 month of directly observed daily F/TDF. Weekly convenience blood samples were collected for plasma TFV and FTC, and intracellular TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP) in peripheral blood mononuclear cells (PBMC) and dried blood spots (DBS). After 2–3 weeks of F/TDF dosing, intensive PK sampling was conducted. PK parameters were estimated using noncompartmental methods. Data were log-transformed and compared between TM and TW, and to historical data among cisgender adults. Plasma TFV exposures were similar between TM and TW [geometric mean ratio (GMR); confidence interval (95% CI): 1.06 (0.89–1.28)], whereas FTC plasma exposures were 21% higher in TM versus TW (95% CI: 1.07–1.38). TFV-DP in PBMC and DBS and FTC-TP in DBS did not differ between TM versus TW after controlling for creatinine clearance (CrCl), but FTC-TP in PBMC remained 46% (95% CI: 1.15–1.86) higher in TM versus TW. All PK exposures were within expected ranges based on historical studies. TM had higher FTC exposures compared with TW, but overall plasma and intracellular exposures for both drugs were within the range of historical studies, suggesting high PrEP efficacy will be retained in adolescent and young adult transgender persons. Registered at ClinicalTrials.gov (NCT03652623)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transgender PersonsAnti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisMaleYoung AdultAdolescentFemaleHumansLeukocytes, MononuclearProspective StudiesEmtricitabineTenofovirReverse Transcriptase InhibitorsHormonesPolyphosphates

Stichwörter der Autor:innen

F/TDFPrEPpharmacologytransgender mentransgender women

Substanzen

Anti-HIV AgentsEmtricitabineTenofovirReverse Transcriptase InhibitorsHormonestriphosphoric acidPolyphosphates

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA.
  • Department of Psychiatry, Stroger Hospital of Cook County, Chicago, Illinois, USA.
  • Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Francisco, San Francisco, California, USA.
  • Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
  • Department of Adolescent Medicine, Children's Hospital of Colorado, Aurora, Colorado, USA.

ORCID-Profile: Jenna Yager

Förderung

  • NIMH NIH HHS

Zitieren

APA

Yager, J., Brooks, K. M., Brothers, J., Mulligan, K., Landovitz, R., Reirden, D., Glenny, C., Malhotra, M., Anderson, P. L., & Hosek, S. (2022). Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones. AIDS Research and Human Retroviruses, 38(11), 840-846. https://doi.org/10.1089/aid.2022.0043

Vancouver

Yager J, Brooks KM, Brothers J, Mulligan K, Landovitz R, Reirden D, et al. Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones. AIDS Research and Human Retroviruses. 2022;38(11):840-846. doi:10.1089/aid.2022.0043

BibTeX
@article{Yager2022,
  author = {Yager, Jenna and Brooks, Kristina M and Brothers, Jennifer and Mulligan, Kathleen and Landovitz, Raphael and Reirden, Daniel and Glenny, Carrie and Malhotra, Meena and Anderson, Peter L and Hosek, Sybil},
  title = {Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones},
  journal = {AIDS Research and Human Retroviruses},
  year = {2022},
  volume = {38},
  number = {11},
  pages = {840--846},
  doi = {10.1089/aid.2022.0043}
}
Kostenlos starten →